RNTX Rein Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1420565 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY15.6%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-100.5%
ROA-87.9%
ROIC (approx.)-85.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets11.2%
Debt / equity0.00x
Current ratio6.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.45x
Accruals ratio-48.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $11.03M | $14.25M | $3.99M | $17.97M | $17.01M |
| SG&A expense | $10.90M | $13.86M | $11.36M | $9.68M | $9.60M |
| Operating income | -$50.63M | -$65.11M | -$16.28M | -$27.65M | -$26.61M |
| Income tax | -$712,000 | -$1.54M | $0 | $0 | $0 |
| Net income | -$49.87M | -$62.88M | -$15.73M | -$27.33M | -$26.16M |
| EBITDA | -$50.63M | -$65.05M | -$16.16M | -$27.48M | -$26.48M |
| EPS (basic) | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 |
| EPS (diluted) | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 25.44M | 17.94M | 4.60M | 4.54M | 4.44M |
| Balance sheet | |||||
| Cash & equivalents | $3.21M | $12.87M | $17.34M | $5.19M | $3.60M |
| Short-term investments | $0 | — | — | $16.05M | $42.33M |
| Current assets | $4.33M | $13.66M | $18.27M | $21.87M | $48.18M |
| PP&E, net | $0 | $1,000 | $19,000 | $70,000 | $128,000 |
| Goodwill | $6.33M | $6.33M | $6.33M | — | — |
| Intangibles | $13.50M | $42.20M | $79.20M | — | — |
| Total assets | $24.16M | $62.19M | $106.01M | $22.01M | $48.48M |
| Current liabilities | $6.18M | $5.75M | $4.38M | $3.38M | $4.51M |
| Total liabilities | $7.24M | $7.80M | $7.71M | $3.38M | $4.58M |
| Shareholders' equity | $16.92M | $54.39M | $98.30M | $18.62M | $43.90M |
| Shares outstanding | 27.55M | 21.67M | 4.89M | 4.54M | 4.53M |
| Cash flow statement | |||||
| Operating cash flow | -$19.36M | -$22.29M | -$19.81M | -$24.86M | -$23.75M |
| Capital expenditure | — | — | — | — | $157,000 |
| Free cash flow | — | — | — | — | -$23.91M |
| Investing cash flow | — | $0 | $16.20M | $26.46M | -$35.92M |
| Financing cash flow | $9.76M | $17.82M | $15.79M | — | $55.66M |
| Depreciation & amortization | $1,000 | $63,000 | $119,000 | $169,000 | $121,000 |
| Stock-based compensation | $2.22M | $1.12M | $1.19M | $2.08M | $2.26M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.